Abiraterone Reactions 1664, p14 - 12 Aug 2017 Torsades de pointes secondary to hypokalaemia: case report A 77-year-old man developed torsades de pointes secondary to hypokalaemia during treatment with abiraterone for metastatic prostate cancer. The man, who had a history of ischaemic heart disease (IHD), atrial fibrillation and coronary artery bypass grafting (CABG), was hospitalised after a syncopal event. He had been receiving abiraterone 250mg four times a day [route of administration not stated] for six months and prednisone. At admission, he had a HR of 70 beats/min and BP of 15/85mm Hg. An ECG revealed a prolonged corrected QT interval (QTc) of 650ms. He had three episodes of TdP which caused syncope. His serum electrolyte level was within normal limit. He had four more episodes of TdP, which required defibrillation, and also several episodes of non-sustained TdP. The The man was treated with isoprenaline to increase his HR and decrease QT interval. Isoprenaline was tapered off on hospital day 2. After receiving 160 mmoL of potassium, his QTc interval significantly improved. A transthoracic echocardiogram revealed mild left ventricular abnormality. Abiraterone was stopped and he was subsequently discharged in a stable condition. At discharge, his QTc was 460ms which remained same at one month follow-up. A diagnosis of TdP secondary to abiraterone-induced hypokalaemia was made at discharge. Naranjo probability score of 7 indicated a probable attribution of hypokalaemia to abiraterone treatment. Author comment: "We present a case of a 77 year-old gentleman with previous coronary artery bypass grafting, admitted to hospital with recurrent torsades de pointes (TdP) due to abiraterone-induced hypokalaemia and prolonged QTc." Khan A, et al. Life threatening torsades de pointes due to abiraterone-induced hypokaelemia in a patient with metastatic prostate cancer. New Zealand Medical Journal 129: 124-127, No. 1445, 18 Nov 2016. Available from: URL: http:// www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2016/ vol-129-no-1445-18-november-2016/7073 - New Zealand 803262452 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1664 (1) – Aug 12, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial